Local pharmacovigilance: all requirements, how to be compliant

Pharmacovigilance in the European Union
Over the years, pharmacovigilance has become a fundamental topic for pharmaceutical companies, which are required to monitor the safety of medicinal products placed on the market through the implementation and maintenance of an adequate pharmacovigilance system.
In the European Union, the responsibilities, processes and activities to be implemented by Marketing Authorisation Holders (MAHs) of medicinal products are described in detail in the “Good Pharmacovigilance Practices” (GVPs), published and kept updated by the European Medicine Agency (EMA).
The central theme is precisely the pharmacovigilance system, and therefore the set of standard operating procedures, processes, flows and relationships between the various parties involved, which allow the correct performance of pharmacovigilance activities, in compliance with the current legislation.
This system is described in the “Pharmacovigilance System Master File” (PSMF), a dynamic document, constantly updated, and therefore also collecting information on all changes that have occurred to the pharmacovigilance system over time.
The responsibility for the pharmacovigilance system lies with the “European Qualified Person for Pharmacovigilance” (EU QPPV), who must be appointed by the MAH and notified to the Competent Authorities. As reported in the GVP, the MAH must ensure that the EU QPPV has sufficient authority to influence the quality system and pharmacovigilance activities.
The EU QPPV is supported by other key figures for the correct execution of the pharmacovigilance processes and compliance with the legislation, such as for example a Deputy EU QPPV (who takes over in case of absence or inability of the EU QPPV), medical staff, a pharmacovigilance unit that deals with various processes under the supervision of the EU QPPV and a quality unit dedicated, among other things, to updating and maintaining the quality system for pharmacovigilance.
Difference between EU-QPPV and Local QPPV
The European Qualified Person for Pharmacovigilance (EU QPPV) must be appointed by the Marketing Authorisation Holder (MAH) and is responsible for the entire pharmacovigilance system on behalf of the MAH in the European Union. Other responsibilities include, for example:
- Acting as a single point of contact for pharmacovigilance for the Competent Authorities of the Member States and for the EMA, 24 hours a day
- Acting as a point of contact for pharmacovigilance inspections
- Having a constant overview of the safety profiles of medicinal products and any safety issues
- Ensuring the correct performance of pharmacovigilance activities and the submission of all documents relating to pharmacovigilance, in accordance with the legislation.
The Local QPPV (sometimes also called Local Pharmacovigilance Responsible, Local Pharmacovigilance Contact Point, LCPPV or Local Safety Officer) is instead responsible for the local pharmacovigilance activities and acts as a point of contact for the national Competent Authority. Not all Member States of the European Union require the appointment of a Local QPPV, the choice depends on the individual countries. In Member States where this role is required by local legislation, the MAHs must therefore appoint a Local QPPV and provide information and contact details to the national Competent Authority.
Local QPPV and local PV activities
The main role of the Local Pharmacovigilance Responsible (also known as Local QPPV, LCCPV, Local Safety Officer etc.) is to act as a contact point for the national Competent Authorities, for any issue relating to the safety of medicinal products authorised in that Member State of the European Union.
In addition, he/she supervises the pharmacovigilance activities that must be carried out at local level, in agreement with the EU QPPV and the MAH. These include, for example, the management of local adverse drug reactions, the management of any follow-ups, the literature screening of non-indexed national journals, the maintenance of a quality system for pharmacovigilance, any contacts with the Competent Authority and much more.
| Differences between EU QPPV and Local QPPV | |
| EU QPPV | Local QPPV |
| Responsible for the pharmacovigilance system in the EU. Appointed by the MAH. | Responsible for local pharmacovigilance activities. Required in some EU Member States. Appointed by the MAH. |
| Single point of contact for EMA and National Competent Authorities. | Point of contact for the National Competent Authority. |
| Supervises pharmacovigilance activities at EU level. | Supervises pharmacovigilance activities at local level. |
Outsourcing local pharmacovigilance activities
Outsourcing the role of the Local Pharmacovigilance Responsible (also known as Local QPPV, LCCPV, Local Safety Officer, etc.) as well as pharmacovigilance activities locally is often a strategic choice for pharmaceutical companies, which can thus ensure compliance with current legislation and have the support of consultants/providers expert in managing pharmacovigilance processes.
Di Renzo Regulatory Affairs has a large team of highly qualified personnel dedicated exclusively to pharmacovigilance. We can therefore assume the role of Local QPPV and Deputy in Italy and handle all activities at a national level, including:
- Assumption of the role of Local QPPV and Deputy in Italy and registration with the “National Pharmacovigilance Network” (RNF) of the Italian Medicines Agency (AIFA)
- Management of reports of adverse drug reaction/ICSRs, translation, QC and forwarding to the EUQPPV/MAH according to the modalities and timing defined in the Safety Data Exchange Agreement (SDEA)
- Management of follow-ups
- Local literature screening on non-indexed national newsletters/journals
- Management and maintenance of a quality system for pharmacovigilance
- Contacts with AIFA for safety issues
- Training of company staff of any national Affiliates or other partners
- Pharmacovigilance intelligence
- Execution of audits to third-parties, where required
- Preparation/review of SDEAs with third parties, where required
- Any other activity related to local pharmacovigilance, if required.
Previous Post
Next Post